Article
Oncology
Ondrej Fiala, Pavel Ostasov, Aneta Rozsypalova, Milan Hora, Ondrej Sorejs, Jan Sustr, Barbora Bendova, Ivan Travnicek, Jan Filipovsky, Jindrich Finek, Tomas Buchler
Summary: The retrospective study analyzed clinical data from 343 patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib or pazopanib, and found that the use of metformin was associated with significantly longer progression-free survival (PFS) and overall survival (OS) compared to non-users. The Cox multivariate analysis confirmed that metformin use remained a significant factor for both PFS and OS, indicating a favorable outcome for mRCC patients receiving sunitinib or pazopanib treatment.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Predrag Nikic, Nada Babovic, Zoran Dzamic, Svetlana Salma, Vesna Stojanovic, Suzana Matkovic, Zoran Pejcic, Kristina Juskic, Ivan Soldatovic
Summary: This retrospective observational study analyzed data from a nationally representative cohort of 759 patients with mRCC in Serbia who received first-line sunitinib or pazopanib. The results showed modest improvements in overall survival for patients with mRCC in real world clinical practice when only sunitinib and pazopanib were available as first-line treatments.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Ondrej Fiala, Pavel Ostasov, Aneta Rozsypalova, Milan Hora, Ondrej Sorejs, Jan Sustr, Barbora Bendova, Ivan Travnicek, Jan Filipovsky, Jindrich Finek, Tomas Buchler
Summary: The use of beta-blockers (BBs) was found to be associated with favorable outcomes for patients with mRCC treated with sunitinib or pazopanib in the first line, with better progression-free survival (PFS) and overall survival (OS) compared to patients not using BBs.
Article
Health Care Sciences & Services
Abeer A. Al-Rabayah, Razan Sawalha, Rawan Fawzi Al Froukh, Rand Al-Bawab, Saad M. Jaddoua
Summary: The study evaluated the cost-effectiveness of pazopanib for treating metastatic renal cell carcinoma (mRCC) in the first-line setting from a payer perspective. Pazopanib was found to be a cost-effective option, leading to incremental savings and an increase in quality-adjusted life years (QALYs) compared to sunitinib. However, the results were sensitive to utility values and the cost of progression health state. Probabilistic sensitivity analysis showed that at KHCC cost-effectiveness threshold values, pazopanib had a 60-70% chance of being cost-effective compared to sunitinib, but this changed when sunitinib's price was reduced by 40%.
JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH
(2021)
Article
Oncology
Francesco Pierantoni, Umberto Basso, Marco Maruzzo, Evelina Lamberti, Davide Bimbatti, Giuseppina Tierno, Eleonora Bergo, Antonella Brunello, Vittorina Zagonel
Summary: In elderly patients with metastatic renal cell carcinoma, CGA assessment can effectively distinguish fit, vulnerable, and frail patients, and significantly impact their survival, disease control, and tolerability.
JOURNAL OF GERIATRIC ONCOLOGY
(2021)
Article
Oncology
Senar Ebinc, Ziya Kalkan, Zeynep Oruc, Zuhat Urakci, Mehmet Kucukoner, Muhammet Ali Kaplan, Abdurrahman Isikdogan
Summary: This study investigates the effectiveness and tolerability of sunitinib and pazopanib in the first-line treatment of metastatic renal cell carcinoma (mRCC). The results show that sunitinib and pazopanib have similar effectiveness and side-effect profiles.
ONCOLOGY IN CLINICAL PRACTICE
(2022)
Article
Oncology
Stefanie Noepel-Duennebacke, Hendrik Juette, Karsten Schulmann, Ulrich Graeven, Rainer Porschen, Jan Stoehlmacher, Susanna Hegewisch-Becker, Arne Raulf, Dirk Arnold, Anke Reinacher-Schick, Aandrea Tannapfel
Summary: High microsatellite instability (MSI-H) tumors were more frequent in right-sided tumors and correlated with mutant BRAF. PD-L1 expression was not correlated with MSI-H status, but in MSI-H tumors the percentage of PD-L1 positive tumors was higher than in MSS tumors.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Review
Oncology
Amit Joshi, Ishan Patel, Pratiksha Kapse, Manmohan Singh
Summary: The safety profile and efficacy of sunitinib alternate schedule (AS) for the treatment of metastatic renal cell carcinoma (mRCC) differs between Asian and non-Asian populations, with variations in dose reductions.
